Filter by tags: Food and Drug Administration Clear all tag filters
7 news articles found
Ontario Power Generation's (OPG) nuclear power plant is set to become the first commercial power reactor in the world to produce molybdenum-99 (Mo-99) after Laurentis Energy Partners and BWXT Medical Ltd completed the installation and initial commissioning of an innovative isotope system.
- Source: World Nuclear News
- Date: Friday, 03 February 2023
- Original article: world-nuclear-news.org/Articles/Darlington-ready-to-produce-medical-radioisotope
An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich has announced the start of commercial production of lutetium-177 at the Bruce NPP in Ontario, Canada.
- Source: NEI Magazine
- Date: Saturday, 29 October 2022
- Original article: neimagazine.com/news/newsproduction-of-lutetium-177-begins-at-bruce-npp-10125876
Belgium’s (Ion Beam Applications (IBA), a leading provider of proton therapy solutions for the treatment of cancer, and US-based NorthStar Medical Radioisotopes, which produces radiopharmaceuticals used for medical imaging and therapeutic applications, on 8 March announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. The collaboration enables companies outside the USA to access the Tc-99m Generation Systems (TCM Generation Systems) that utilise NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines.
- Source: NEI Magazine
- Date: Tuesday, 16 March 2021
- Original article: neimagazine.com/news/newsiba-and-northstar-medical-radioisotopes-expand-collaboration-8601282
The US Department of Energy's National Nuclear Security Administration (NNSA) has awarded cooperative agreements for the production of molybdenum-99 to three US companies. The announcement came as one of the companies - Shine Medical Technologies - submitted an application to the Nuclear Regulatory Commission (NRC) to produce medical isotopes at its new production facility in Janesville, Wisconsin.
- Source: World Nuclear News
- Date: Tuesday, 23 July 2019
- Original article: world-nuclear-news.org/Articles/Three-US-companies-awarded-funds-for-Mo-99-product
US-based NorthStar Medical Radioisotopes has completed construction on its 20,000 square foot molybdenum-99 (Mo-99) processing facility in Beloit, Wisconsin, with equipment installation underway.
- Source: NEI Magazine
- Date: Friday, 19 July 2019
- Original article: neimagazine.com/news/newsnorthstar-completes-mo-99-facility-7322727
US-based NorthStar Medical Technologies of the USA has closed a $100 million financing with Oberland Capital Management. NorthStar received $75 million at closing with the ability to draw an additional $25 million before 31 December 2020 at the Company’s option.
- Source: NEI Magazine
- Date: Friday, 26 April 2019
- Original article: neimagazine.com/news/newsnorthstar-wins-financing-from-oberland-7171164
US-based NorthStar Medical Radioisotopes and Belgium’s Ion Beam Applications (IBA) have signed a contract under which IBA would supply up to eight Rhodotron TT300 HE electron beam accelerators to NorthStar, which has issued purchase orders for the first two units. Six more will be delivered in coming years.
- Source: NEI Magazine
- Date: Thursday, 04 April 2019
- Original article: neimagazine.com/news/newsbelgiums-iba-to-supply-accelerators-to-northstar-7136876